Exact Mass: 519.2758
Exact Mass Matches: 519.2758
Found 284 metabolites which its exact mass value is equals to given mass value 519.2758
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
[(3S,5S,7S)-7-{(1E,3E)-5-[(2S,3S,5R,6R)-5-{[(2Z,4S)-4-(acetyloxy)pent-2-enoyl]amino}-3,6-dimethyltetrahydro-2H-pyran-2-yl]-3-methylpenta-1,3-dien-1-yl}-1,6-dioxaspiro[2.5]oct-5-yl]acetic acid
[(2S,5S,6R)-6-{(1E,3E)-5-[(2S,3S,5R,6R)-5-{[(2Z,4S)-4-(acetyloxy)pent-2-enoyl]amino}-3,6-dimethyltetrahydro-2H-pyran-2-yl]-3-methylpenta-1,3-dien-1-yl}-5-hydroxy-4-methylidenetetrahydro-2H-pyran-2-yl]acetic acid
4,5-dihydro-7-O-descarbamoyl-7-hydroxygeldanamycin
Ala His His Arg
Ala His Arg His
Ala Arg His His
Glu Phe Lys Pro
Glu Phe Pro Lys
Glu Ile Lys Met
Glu Ile Met Lys
Glu Lys Phe Pro
Glu Lys Ile Met
Glu Lys Leu Met
Glu Lys Met Ile
Glu Lys Met Leu
Glu Lys Pro Phe
Glu Leu Lys Met
Glu Leu Met Lys
Glu Met Ile Lys
Glu Met Lys Ile
Glu Met Lys Leu
Glu Met Leu Lys
Glu Pro Phe Lys
Glu Pro Lys Phe
Phe Glu Lys Pro
Phe Glu Pro Lys
Phe Lys Glu Pro
Phe Lys Pro Glu
Phe Pro Glu Lys
Phe Pro Lys Glu
Phe Pro Arg Thr
Phe Pro Thr Arg
Phe Arg Pro Thr
Phe Arg Thr Pro
Phe Thr Pro Arg
Phe Thr Arg Pro
His Ala His Arg
His Ala Arg His
His His Ala Arg
His His Arg Ala
His Arg Ala His
His Arg His Ala
Ile Glu Lys Met
Ile Glu Met Lys
Ile Lys Glu Met
Ile Lys Met Glu
Ile Met Glu Lys
Ile Met Lys Glu
Ile Met Arg Thr
Ile Met Thr Arg
Ile Pro Gln Tyr
Ile Pro Tyr Gln
Ile Gln Pro Tyr
Ile Gln Tyr Pro
Ile Arg Met Thr
Ile Arg Thr Met
Ile Thr Met Arg
Ile Thr Arg Met
Ile Thr Thr Trp
Ile Thr Trp Thr
Ile Trp Thr Thr
Ile Tyr Pro Gln
Ile Tyr Gln Pro
Lys Glu Phe Pro
Lys Glu Ile Met
Lys Glu Leu Met
Lys Glu Met Ile
Lys Glu Met Leu
Lys Glu Pro Phe
Lys Phe Glu Pro
Lys Phe Pro Glu
Lys Ile Glu Met
Lys Ile Met Glu
Lys Lys Met Asn
Lys Lys Asn Met
Lys Leu Glu Met
Lys Leu Met Glu
Lys Met Glu Ile
Lys Met Glu Leu
Lys Met Ile Glu
Lys Met Lys Asn
Lys Met Leu Glu
Lys Met Asn Lys
Lys Asn Lys Met
Lys Asn Met Lys
Lys Pro Glu Phe
Lys Pro Phe Glu
Leu Glu Lys Met
Leu Glu Met Lys
Leu Lys Glu Met
Leu Lys Met Glu
Leu Met Glu Lys
Leu Met Lys Glu
Leu Met Arg Thr
Leu Met Thr Arg
Leu Pro Gln Tyr
Leu Pro Tyr Gln
Leu Gln Pro Tyr
Leu Gln Tyr Pro
Leu Arg Met Thr
Leu Arg Thr Met
Leu Thr Met Arg
Leu Thr Arg Met
Leu Thr Thr Trp
Leu Thr Trp Thr
Leu Trp Thr Thr
Leu Tyr Pro Gln
Leu Tyr Gln Pro
Met Glu Ile Lys
Met Glu Lys Ile
Met Glu Lys Leu
Met Glu Leu Lys
Met Ile Glu Lys
Met Ile Lys Glu
Met Ile Arg Thr
Met Ile Thr Arg
Met Lys Glu Ile
Met Lys Glu Leu
Met Lys Ile Glu
Met Lys Lys Asn
Met Lys Leu Glu
Met Lys Asn Lys
Met Leu Glu Lys
Met Leu Lys Glu
Met Leu Arg Thr
Met Leu Thr Arg
Met Asn Lys Lys
Met Arg Ile Thr
Met Arg Leu Thr
Met Arg Thr Ile
Met Arg Thr Leu
Met Thr Ile Arg
Met Thr Leu Arg
Met Thr Arg Ile
Met Thr Arg Leu
Asn Lys Lys Met
Asn Lys Met Lys
Asn Met Lys Lys
Pro Glu Phe Lys
Pro Glu Lys Phe
Pro Phe Glu Lys
Pro Phe Lys Glu
Pro Phe Arg Thr
Pro Phe Thr Arg
Pro Ile Gln Tyr
Pro Ile Tyr Gln
Pro Lys Glu Phe
Pro Lys Phe Glu
Pro Leu Gln Tyr
Pro Leu Tyr Gln
Pro Gln Ile Tyr
Pro Gln Leu Tyr
Pro Gln Tyr Ile
Pro Gln Tyr Leu
Pro Arg Phe Thr
Pro Arg Thr Phe
Pro Thr Phe Arg
Pro Thr Arg Phe
Pro Tyr Ile Gln
Pro Tyr Leu Gln
Pro Tyr Gln Ile
Pro Tyr Gln Leu
Gln Ile Pro Tyr
Gln Ile Tyr Pro
Gln Leu Pro Tyr
Gln Leu Tyr Pro
Gln Pro Ile Tyr
Gln Pro Leu Tyr
Gln Pro Tyr Ile
Gln Pro Tyr Leu
Gln Tyr Ile Pro
Gln Tyr Leu Pro
Gln Tyr Pro Ile
Gln Tyr Pro Leu
Arg Ala His His
Arg Phe Pro Thr
Arg Phe Thr Pro
Arg His Ala His
Arg His His Ala
Arg Ile Met Thr
Arg Ile Thr Met
Arg Leu Met Thr
Arg Leu Thr Met
Arg Met Ile Thr
Arg Met Leu Thr
Arg Met Thr Ile
Arg Met Thr Leu
Arg Pro Phe Thr
Arg Pro Thr Phe
Arg Thr Phe Pro
Arg Thr Ile Met
Arg Thr Leu Met
Arg Thr Met Ile
Arg Thr Met Leu
Arg Thr Pro Phe
Thr Phe Pro Arg
Thr Phe Arg Pro
Thr Ile Met Arg
Thr Ile Arg Met
Thr Ile Thr Trp
Thr Ile Trp Thr
Thr Leu Met Arg
Thr Leu Arg Met
Thr Leu Thr Trp
Thr Leu Trp Thr
Thr Met Ile Arg
Thr Met Leu Arg
Thr Met Arg Ile
Thr Met Arg Leu
Thr Pro Phe Arg
Thr Pro Arg Phe
Thr Arg Phe Pro
Thr Arg Ile Met
Thr Arg Leu Met
Thr Arg Met Ile
Thr Arg Met Leu
Thr Arg Pro Phe
Thr Thr Ile Trp
Thr Thr Leu Trp
Thr Thr Trp Ile
Thr Thr Trp Leu
Thr Trp Ile Thr
Thr Trp Leu Thr
Thr Trp Thr Ile
Thr Trp Thr Leu
Trp Ile Thr Thr
Trp Leu Thr Thr
Trp Thr Ile Thr
Trp Thr Leu Thr
Trp Thr Thr Ile
Trp Thr Thr Leu
Tyr Ile Pro Gln
Tyr Ile Gln Pro
Tyr Leu Pro Gln
Tyr Leu Gln Pro
Tyr Pro Ile Gln
Tyr Pro Leu Gln
Tyr Pro Gln Ile
Tyr Pro Gln Leu
Tyr Gln Ile Pro
Tyr Gln Leu Pro
Tyr Gln Pro Ile
Tyr Gln Pro Leu
ibha#22
A 4-O-(1H-indol-3-ylcarbonyl)ascaroside that is icas#22 in which the pro-R hydrogen beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.
ibho#22
An omega-hydroxy fatty acid ascaroside that is bhos#22 in which the hydroxy group at position 4 of the ascarylopyranose moiety has been has been converted to the corresponding 1H-indole-3-carboxylate ester. It is a metabolite of the nematode Caenorhabditis elegans.
Bomedemstat
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
(3R)-13-[[3,6-Dideoxy-4-O-(1H-indol-3-ylcarbonyl)-alpha-L-arabino-hexopyranosyl]oxy]-3-hydroxytridecanoic acid
(3R,12R)-12-[[3,6-Dideoxy-4-O-(1H-indol-3-ylcarbonyl)-alpha-L-arabino-hexopyranosyl]oxy]-3-hydroxytridecanoic acid
N-[[(4R,5S)-8-[3-(dimethylamino)prop-1-ynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(4S,5S)-8-[3-(dimethylamino)prop-1-ynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(4S,5R)-8-[3-(dimethylamino)prop-1-ynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(4S,5S)-8-[3-(dimethylamino)prop-1-ynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(4R,5R)-8-[3-(dimethylamino)prop-1-ynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(4R,5S)-8-[3-(dimethylamino)prop-1-ynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(4S,5R)-8-[3-(dimethylamino)prop-1-ynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(4R,5R)-8-[3-(dimethylamino)prop-1-ynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(3-phenylprop-1-ynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(3-phenylprop-1-ynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(3-phenylprop-1-ynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(3-phenylprop-1-ynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(3-phenylprop-1-ynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(3-phenylprop-1-ynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(3-phenylprop-1-ynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(3-phenylprop-1-ynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-oxanecarboxamide
KRAS inhibitor-10
KRAS inhibitor-10 (compound 11) selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a?tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1[1].